Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event Reporting

Cancer Statistics, 2010

2010 • 12,557 citations

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

2005 • 4,040 citations

A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions

2002 • 1,019 citations

Perspectives on the Use of Data Mining in Pharmacovigilance

2005 • 239 citations

Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes

2009 • 220 citations

Impact of Safety Alerts on Measures of Disproportionality in Spontaneous Reporting Databases

2007 • 216 citations

Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non‐case study in the French pharmacovigilance system database

1997 • 134 citations

Antimicrobials and the Risk of Torsades de Pointes

2010 • 119 citations

Effects of Pioglitazone, a Peroxisome Proliferator–Activated Receptor Gamma Agonist, on the Urine and Urothelium of the Rat

2009 • 78 citations

Glucocorticoid therapy and risk of bladder cancer

2009 • 60 citations

Changes in Glitazone Use Among Office-Based Physicians in the U.S., 2003–2009

2010 • 53 citations